INFO & CONTACTS:  +39 02 2390 1

Phase I open-label, multi-center study to evaluate the safety, tolerability, dosimetry, and preliminary activity of [177Lu]Lu-NNS309 in patients with pancreatic, lung, breastand colorectal cancers

Phase: Phase I clinical trials

Principal Investigator: Dott. Maccauro Marco

Main Facility: Medicina Nucleare

Drug: [177Lu]Lu-NNS309

Pathologies: Breast cancer (TNBC), Colorectal cancer (CRC), Pancreatic cancer, Lung cancer

The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of [177Lu]Lu-NNS309 and the safety and imaging properties of [68Ga]Ga-NNS309 in patients aged ≥ 18 years with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), HR+/HER2- ductal and lobular breast cancer (BC), triple negative breast cancer (TNBC) and colorectal cancer (CRC). 

Last update: 22/04/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe